Sign In
Buy SRPT
$14.86
-0.700 (-4.50%)
At Close: Jul 31, 2026
Sarepta Plans FDA Filings Seeking Full Approval for Two DMD Therapies
11:50am, Friday, 20'th Mar 2026
SRPT plans FDA filings to convert Amondys 45 and Vyondys 53 to full approvals, leveraging new data despite a missed endpoint in its confirmatory study.
Sarepta To Request FDA For Traditional Approvals For Duchenne Drugs
11:51am, Thursday, 19'th Mar 2026
The stock's decline comes as the company plans to submit supplemental new drug applications to the U.S. Food and Drug Administration (FDA) by the end of April, as detailed in the regulatory update.
Sarepta Provides Regulatory Update on AMONDYS 45® and VYONDYS 53®
08:30am, Thursday, 19'th Mar 2026
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today provided an update on its ongoing regulatory interactions
SRPT Stock Up as Enrollment Begins in DMD Gene Therapy Safety Study
11:35am, Tuesday, 17'th Mar 2026
Sarepta gains as enrollment begins in a new ENDEAVOR study cohort testing a sirolimus regimen to improve Elevidys safety in DMD patients.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced screening and enrollment are underway in Cohort
Sarepta Therapeutics, Inc. (SRPT) Presents at TD Cowen 46th Annual Health Care Conference Transcript
05:32pm, Tuesday, 03'rd Mar 2026
Sarepta Therapeutics, Inc. (SRPT) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Sarepta Therapeutics Announces Call for Applications for the 9th Annual Route 79, The Duchenne Scholarship Program
09:00am, Friday, 27'th Feb 2026
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the official opening of Route 79, The Duchenne
Sarepta Therapeutics, Inc. $SRPT Stock Position Lowered by AXQ Capital LP
03:29am, Friday, 27'th Feb 2026
AXQ Capital LP decreased its position in Sarepta Therapeutics, Inc. (NASDAQ: SRPT) by 72.8% in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities an
Sarepta Q4 Loss Wider Than Expected, Sales Beat Estimates
11:32am, Thursday, 26'th Feb 2026
SRPT posts a wider Q4 loss as Elevidys sales tumble, but revenues top estimates and 2026 guidance outlines a cautious recovery path.
Compared to Estimates, Sarepta Therapeutics (SRPT) Q4 Earnings: A Look at Key Metrics
10:31am, Thursday, 26'th Feb 2026
Although the revenue and EPS for Sarepta Therapeutics (SRPT) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare w
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will present at the Muscular Dystrophy Association (MDA) Clinic
Sarepta CEO To Jump Ship After 'Tumultuous' Year
05:52am, Thursday, 26'th Feb 2026
On Wednesday, Sarepta Therapeutics reported an adjusted loss of $3.58 per share, missing the Wall Street estimate loss of $1.31. Sales reached $442.93 million, beating the consensus of $391.92 million
Sarepta Therapeutics CEO Ingram to retire by year end
05:05am, Thursday, 26'th Feb 2026
Sarepta Therapeutics CEO Douglas Ingram has decided to step down by the end of 2026 or upon the appointment of his replacement, the company said in a regulatory filing.
Sarepta Therapeutics, Inc. (SRPT) Q4 2025 Earnings Call Transcript
08:27pm, Wednesday, 25'th Feb 2026
Sarepta Therapeutics, Inc. (SRPT) Q4 2025 Earnings Call Transcript
Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Developments
04:05pm, Wednesday, 25'th Feb 2026
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the fourth quarter and ful
